Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $15.57 Consensus Target Price from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $15.57.

A number of brokerages have weighed in on FULC. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. Oppenheimer reduced their price target on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th. The Goldman Sachs Group raised shares of Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the company from $6.00 to $15.00 in a report on Monday, May 13th. Royal Bank of Canada assumed coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Fulcrum Therapeutics in a report on Monday, May 20th. They set an “overweight” rating and a $23.00 price objective for the company.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in Fulcrum Therapeutics by 7.6% during the 3rd quarter. FMR LLC now owns 5,975,416 shares of the company’s stock valued at $26,531,000 after purchasing an additional 421,676 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Fulcrum Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after purchasing an additional 18,681 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Fulcrum Therapeutics by 4.3% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,406,422 shares of the company’s stock valued at $10,685,000 after purchasing an additional 100,000 shares during the last quarter. Vestal Point Capital LP bought a new position in Fulcrum Therapeutics during the 4th quarter valued at about $6,919,000. Finally, ADAR1 Capital Management LLC bought a new position in Fulcrum Therapeutics during the 4th quarter valued at about $4,302,000. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Stock Down 1.3 %

Shares of FULC opened at $6.20 on Friday. The company’s fifty day moving average is $7.40 and its 200-day moving average is $7.99. Fulcrum Therapeutics has a 12 month low of $3.09 and a 12 month high of $13.70. The firm has a market cap of $385.33 million, a price-to-earnings ratio of -3.87 and a beta of 2.34.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. As a group, research analysts predict that Fulcrum Therapeutics will post -1.24 earnings per share for the current fiscal year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.